-
Magnetic Stimulation Targets GABRE in Schizophrenia Mice
2026-09-17
This Molecular Psychiatry study identifies the GABAA receptor epsilon subunit, GABRE, in the left prelimbic cortex as a mechanistic target of precisely delivered magnetic stimulation. Using behavioral, synaptic, genetic, and molecular experiments, the authors show that GABRE reduction is associated with reversal of schizophrenia-like phenotypes in mice and implicate p62/SQSTM1–GABARAP trafficking in the response.
-
hiPSC Intestinal Organoids for Pharmacokinetic Studies
2026-09-17
Saito and colleagues established a direct three-dimensional culture approach for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids can be cryopreserved, expanded, and differentiated into intestinal epithelial cells with enterocyte CYP and transporter activities, providing a more human-relevant platform for pharmacokinetic research than conventional animal or Caco-2 models.
-
From Cortical DNA Repair to Better cDNA Decisions
2026-09-16
A mechanistic and strategic guide to using robust reverse transcription when studying ATF4-dependent DNA repair and CUX2+ cortical neuron development.
-
FH1: A Decision Framework for iHep Maturation
2026-09-16
Explore how the FH1 small molecule can be evaluated as a multidimensional maturation variable in iPS-derived hepatocyte cultures. This article connects albumin, CYP3A4, AFP, morphology, and time-resolved assay design with insights from light-regulated gene therapy research.
-
4μ8C Workflows for IRE1 RNase Inhibition
2026-09-15
Build cleaner ER-stress experiments with 4μ8C, a selective IRE1α RNase inhibitor suited to hypoxia, cancer-cell, and unfolded protein response studies. This guide combines dosing, controls, orthogonal readouts, and a cautious assay bridge to emerging ADP-ribosylation and ubiquitin-pathway research.
-
PTEN mRNA: From Signaling Logic to Translation
2026-09-15
PTEN restoration is becoming a strategic approach for studying PI3K/Akt-driven resistance, but translational success depends on more than gene selection. This article connects Cap 1 and pseudouridine-modified in vitro transcribed mRNA with delivery design, pharmacodynamic validation, and the practical decisions that move PTEN biology toward reproducible cancer research.
-
SNAI1–PIK3R2/p-EphA2 Axis in Thymic Tumors
2026-09-14
The 2024 reference study identifies SNAI1 as a transcriptional hub that promotes epithelial–mesenchymal transition and sustains cancer stem cell-like properties in thymic epithelial tumors. By integrating transcriptomic, single-cell, chromatin, protein-interaction, and phosphoproteomic analyses, the authors connect SNAI1 to a PIK3R2/p-EphA2–GSK3β/β-catenin signaling axis and provide a mechanistic basis for future therapeutic investigation.
-
FLOT1–FOSL2–EphA2 Axis in Alzheimer’s Disease
2026-09-14
A 2026 Neuropharmacology study identifies a FLOT1–FOSL2–EphA2 signaling axis that promotes pro-inflammatory microglial polarization through p38/MAPK signaling in APP/PS1 mice. Silencing FLOT1 reduced neuroinflammatory responses and improved spatial memory, providing a mechanistic framework for studying how membrane-associated proteins regulate transcription and microglial state in Alzheimer’s disease.
-
Primary Antibody Dilution Buffer for PCNSL Signal Control
2026-09-13
Learn how Primary Antibody Dilution Buffer K1200 can support more defensible PCNSL immunostaining by separating biological signal from assay artifacts. This article connects buffer chemistry, single-cell metabolic findings, spatial validation, and practical control design.
-
IR-1061 Near Infrared Fluorescent Dye Workflow
2026-09-12
IR-1061 combines strong OTN-NIR fluorescence with a DMSO-compatible preparation workflow for deep-tissue optical studies. This guide translates its formulation, nanoparticle-encapsulation, imaging, and troubleshooting considerations into practical assay decisions without overstating diagnostic or therapeutic readiness.
-
Epacadostat (INCB024360): From Enzyme to Immune Context
2026-09-11
Epacadostat (INCB024360) is a selective, orally active IDO1 inhibitor that helps translational researchers connect enzyme-level target engagement with immune-function and tumor-microenvironment readouts. This thought-leadership guide integrates standardized whole-blood stimulation, assay design, checkpoint-combination strategy, and practical limitations for immuno-oncology research.
-
Orientia, RIPK3, and the Limits of Necroptosis Escape
2026-09-11
A 2025 study shows that Orientia tsutsugamushi lowers cellular RIPK3 abundance but cannot block necroptosis after the RIPK3–MLKL pathway is forcibly activated. The work separates pathogen-mediated reduction of a pathway component from true pathway inhibition, providing a useful framework for interpreting programmed cell death assays in intracellular infection.
-
2-Thio-dCTP for Reproducible DNA Assays
2026-09-10
A scenario-based guide to using 2-Thio-dCTP (SKU B8104) in DNA polymerase, site-specific modification, and DNA–protein interaction workflows. It clarifies assay compatibility, handling, interpretation, and vendor-selection criteria for researchers studying proliferation or cytotoxicity mechanisms.
-
Perifosine (KRX-0401): From Akt Biology to Translation
2026-09-10
A translational perspective on Perifosine as an Akt-directed research tool, connecting apoptosis assays, radiosensitization, and pathway context while defining the limits of extrapolating cancer data into neuroprotection.
-
Alda 1: ALDH2 Activator Research Workflows
2026-09-09
Alda 1 supports mechanism-driven studies of aldehyde detoxification, cardiomyocyte proliferation, cardiac stress, and radiation-related skin injury. This guide connects biochemical validation with cardiac ischemia research and radiation-induced dermatitis mitigation while emphasizing controls, assay selection, and troubleshooting.